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INTRODUCTION
Dyspnea is an unpleasant sensation of labored or difficult 
breathing.1 It is one of the cardinal symptoms of asthma, along 
with cough, wheezing, and chest tightness. Furthermore, 
among asthmatic patients who visited the emergency depart-
ment because of increased symptom severity, dyspnea was the 
most commonly reported complaint.2 Recurrent episodes of 
dyspnea or other relevant symptoms indicating airway obstruc-
tion are essential for the diagnosis of asthma, as well as the ex-
clusion of other possible causes.3
The bronchial provocation test is indicated to replicate asth-
ma presentation by stimulating bronchial contraction. By grad-
ually increasing the stimulus, we can verify the presence of 
bronchial hyperresponsiveness (BHR), which is a fall in the 
forced expiratory volume in 1 second (FEV1) beyond a certain 
threshold in asthmatic subjects.4,5 In general, the amount of 
stimulus that can lead to a >20% bronchial obstruction is re-
garded as an indicator of BHR.6 In young children, bronchial 
obstruction can be assessed using the relevant physical find-
ings, typically the emergence of wheezing or desaturation. 
However, dyspnea is not widely utilized as an indicator of asth-
ma provocation despite its universal presentation. Additionally, 
it is controversial whether the degree of dyspnea is proportion-
ate with lung function decline, or whether the relationship var-
ies according to the degree of BHR (BHR grade).7-9
In this study, we intended to explore the clinical significance of 
dyspnea during induced bronchoconstriction. We measured 
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changes in the severity of dyspnea during bronchial provocation 
tests in children with asthma and evaluated their association 
with lung function reduction. We aimed to verify whether dys-
pnea perception correlates with lung function decline and 
whether there are other variables that affect dyspnea perception.
MATERIALS AND METHODS
Subjects 
We retrospectively analyzed deidentified data from another 
study that evaluated the relationship between a modified Borg 
(mBorg) scale and the pictogram-based dyspnea scale during 
induced bronchoconstriction in children with clinical asthma.10 
(approval No. H-1302-019-462) The study recruited 73 asthmat-
ic children, aged ≥6 years, who visited the allergy clinic in our 
institute. All subjects had a history of clinical asthma, such as 
chronic cough, episodic dyspnea, and/or wheezing within the 
past year. Patients with a history of near-fatal asthma, major ex-
acerbations necessitating the use of systemic corticosteroids, or 
serious respiratory diseases other than asthma, such as bron-
chopulmonary dysplasia or bronchiectasis, were excluded from 
the study. This analysis was approved by the Institutional Ethics 
Committee of the Seoul National University Hospital/Seoul Na-
tional University College of Medicine (approval No. H-1704-
112-847) and the requirement for consent was waived.
Pulmonary function test and bronchial provocation test
Forced vital capacity (FVC) and FEV1 were measured via 
forced expiratory maneuvers according to standards that met 
the American Thoracic Society (ATS) criteria11 using a spirome-
ter (MicroPlus; CareFusion, Basingstoke, UK). All subjects were 
requested to stop taking inhaled corticosteroids and leukotri-
ene receptor antagonists for 2 weeks, antihistamines for 1 week, 
bronchodilators and other medications for 48 hours, and short-
acting β2-agonists for 8 hours before the tests. None of our sub-
jects had any symptoms of upper respiratory tract infections in 
the 2 weeks preceding the tests. Before we proceeded to per-
form the bronchial challenges, the patients were trained to con-
duct spirometry in a reproducible way (i.e., a coefficient of vari-
ation of FEV1 in 3 consecutive flow-volume curves of <5%), 
and they were required to have an FEV1 of at least 70% of the 
predicted value.
The bronchial provocation test was carried out according to 
the ATS guidelines.6 Fresh solutions of methacholine chloride 
(Sigma-Aldrich, St. Louis, MO, USA) were prepared in buffered 
saline solution at concentrations of 0.625, 2.5, 5, 25, and 100 
mg/mL. We could not apply Provocholine® (methacholine 
chloride USP; Methapharm Inc., Ontario, Canada) because it 
was commercially unavailable in our country during the study 
period. First, the subjects were instructed to inhale a dose of 
0.9% saline 5 times. After a 2-minute interval, we assessed the 
subjects’ dyspnea and FEV1, and recorded these measure-
ments as the baseline readings. These measurements were 
then repeated 2 minutes after 5 inhalations of doses of 0.625, 
2.5, 5, 25, and 100 mg/mL methacholine. The test was terminat-
ed if FEV1 showed a decrease of more than 20% compared to 
the baseline value, or if FEV1 did not decrease by more than 
20% at the last dose-step. For subjects who exhibited a percent-
age fall in the FEV1 from baseline (ΔFEV1%) of ≥20%, the pro-
vocative concentration of methacholine causing the ΔFEV1% of 
20% (PC20) was calculated by interpolation from a log-linear 
graph.
Assessment of dyspnea perception
During the bronchial challenges, the severity of perceived 
dyspnea was assessed by the mBorg scale12 and the pediatric 
dyspnea scale (PDS).13 The Borg scale is a vertical list with la-
beled categories (0-10) describing increasing intensities of dys-
pnea (0 “nothing at all” and 10 “maximal”). We used a modified 
version of the Borg scale that was translated into the Korean 
language. Because the Korean version of the mBorg scale has 
previously been validated but the PDS has not, we selected the 
mBorg scale to assess the relationship with lung function pa-
rameters. Prior to the bronchial provocation, we explained the 
mBorg scale to the participants and gave them time to familiar-
ize themselves with the scale. Before FEV1 measurement on 
each dose-step, we asked the children “How severe was your 
breathlessness after this inhalation?” We did not remind sub-
jects of their dyspnea scores in the previous step. Throughout 
the provocation test, the subjects were blinded to their lung 
function results.
Statistical analysis
The R statistical software (version 3.3.2; R Project for Statistical 
Computing, Vienna, Austria), are used for data analysis. Con-
tinuous variables, such as age, height, weight, FEV1, and 
ΔFEV1% were presented as the mean±standard deviation. 
Dyspnea scores are presented as the median and the interquar-
tile range. The Kruskal-Wallis test was utilized to assess the 
group difference in the medians of the last dose-step mBorg 
scores; the trend of these scores across the BHR groups was ex-
amined by the Jonckheere-Terpstra test.14 A linear mixed model 
analysis15 was performed to evaluate the relationship among 
the mBorg, ΔFEV1%, methacholine dose-step, and BHR grade. 
P values were obtained using a likelihood ratio test of the full 
model with the effect in question against the model without the 
effect in question. The significance level was statistically signifi-
cant when a P value was less than 0.05.
RESULTS
A total of 73 asthmatic children underwent the methacholine 
provocation test. Table presents their baseline characteristics, 
including the profile of BHR grades and mBorg scores. The 
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mean age of the participants was 10.8 years (48% [35/73] of 
them aged <10 years) and 56.2% were male. Forty-three sub-
jects (43/73, 58.9%) presented significant bronchoconstriction, 
defined as a ΔFEV1% ≥20% on any dose-step. Thirty children 
had a ΔFEV1% of <20% even after undergoing the final dose-
step of the bronchial challenges. If we define BHR as the PC20 
<16 mg/mL, 28 subjects (28/73, 38.4%) had BHR. We then as-
signed a BHR grade to all the subjects, based on the dose-step 
that they reached during the test (Table). This classification was 
performed as follows: group I (n=6) with ΔFEV1% > 20% at the 
first dose-step, indicating severe BHR; group II (n=4) with 
ΔFEV1% >20% at the second dose-step; and similarly, for 
groups III (n=5) and IV (n=18). Group V (n=40) consisted of 
those subjects whose ΔFEV1% remained <20% after the fourth 
dose-step and ended up receiving the final dose-step.
There was no significant difference in the median last dose-
step mBorg scores between subjects who had BHR and those 
who did not (P=0.272), neither was there a significant differ-
ence among the 5 BHR groups (P=0.596). The median of last 
dose-step mBorg scores increased from 2 to 4 as the group 
number increased from I to IV (Table), whereas the trend was 
not statistically significant, even when we confined the analysis 
to subjects in groupd I to IV, i.e., those who exhibited significant 
bronchoconstriction at methacholine concentrations <25 mg/
mL (n=33, P=0.405, Jonckheere-Terpstra test).
Fig. 1 depicts the changes in ΔFEV1% across dose-steps with 
regard to the subjects’ BHR group. The linear mixed effect anal-
ysis showed that the methacholine dose-step affected ΔFEV1% 
(χ2 [1]=233.48, P<0.001), increasing by 3.90±0.21 (standard er-
ror). The BHR grades also affected ΔFEV1% (χ2 [1]=96.47, 
P<0.001), decreasing by -4.87±0.40.
The changes in mBorg scores for increasing dose-steps with 
regard to the subjects’ BHR group are shown in Fig. 2. Except 
for one point (BHR group IV at a methacholine concentration 
of 2.5 mg/mL), the median mBorg score increased with the 
dose-steps in all BHR groups. For a given dose-step, the median 
mBorg score decreased when the BHR group number in-
creased. The linear mixed effect analysis showed that the 
methacholine dose-step affected the mBorg scores (χ2 [1]=  
162.88, P<0.001), increasing by 0.480±0.033 (standard error). 
The BHR grades also affected the mBorg scores (χ2 [1]=5.43, 
P=0.020), decreasing by -0.252±0.106.
Fig. 3 presents the distribution of mBorg scores according to 
ΔFEV1% by methacholine dose-steps. When we developed a 
model to predict mBorg scores by ΔFEV1%, dose-step, and 
BHR grades, we found that the ΔFEV1% and methacholine 
dose-step affected the mBorg score, elevating it by 0.039 
(ΔFEV1%, χ2 [1]=21.06, P<0.001) and 0.327 (methacholine 
dose-step, χ2 [1]=47.45, P<0.001), respectively. BHR grades, 
however, did not show a significant contribution (χ2 [1]=0.315, 
P=0.574). A significant interaction was observed between the 
methacholine dose step and ΔFEV1% (χ2 [1]=16.20, P<0.001).
DISCUSSION
When assessing the degree of dyspnea in asthmatic children 
during induced bronchoconstriction, we noticed a trend of de-
creasing lung function and increasing degrees of dyspnea as 
the dose-steps increased. We also observed that the trend was 
more evident when children had more severe BHR. It was a 
universal finding that subjects perceived more severe dyspnea 
as their lung function became worse, regardless of BHR status. 
Table. Characteristics of the study subjects
Variable No./total No. (%) P value
Sex -
   Male 41/73 (56.1)
Height (cm) 142.1±16.3 -
Age (year) 10.8±3.3 -
   <10 35/73 (48.0)
   ≥10 and <13 19/73 (26.0)
   ≥13 19/73 (26.0)
Controller -
   None 51/73 (69.9)
   LTRA 10/73 (13.7)
   ICS 9/73 (12.3)
   ICS/LABA combination 3/73 (4.1)
BHR (mg/mL) -
   PC20 <16 28/73 (38.4)
   PC20 ≥16 and <100 15/73 (20.5)
   PC20 ≥100 30/73 (41.1)
BHR grade -
   I (PC20 <0.6 mg/mL) 6/73 (8.2)
   II (0.6 mg/mL ≤PC20 <2.5 mg/mL) 4/73 (5.5)
   III (2.5 mg/mL ≤PC20 <5.0 mg/mL) 5/73 (6.8)
   IV (5.0 mg/mL ≤PC20 <25.0 mg/mL) 18/73 (24.7)
   V (PC20 ≥25.0 mg/mL) 40/73 (54.8)
Last dose-step mBorg score* 0.272
   BHR (PC20 <16 mg/mL) 3.0 (0-7.0)
   Non-BHR (PC20 ≥16 mg/mL) 3.0 (0-5.0)
Last dose-step mBorg score† 0.596
   I (PC20 <0.6 mg/mL) 2.0 (0.0-5.0)
   II (0.6 mg/mL ≤PC20 <2.5 mg/mL) 3.0 (3.0-4.0)
   III (2.5 mg/mL ≤PC20 <5.0 mg/mL) 3.0 (3.0-5.0)
   IV (5.0 mg/mL ≤PC20 <25.0 mg/mL) 4.0 (0.0-7.0)
   V (PC20 ≥25.0 mg/mL) 3.0 (0.0-5.0)
Values are presented as number (%), mean±SD, or median (range).
LTRA, leukotriene receptor antagonist; ICS, inhaled corticosteroid; LABA, long-
acting beta agonist; BHR, bronchial hyperresponsiveness; PC20, ΔFEV1% of 
20%; mBorg, modified Borg; SD, standard deviation. 
*Analysis of difference in scores between subjects who had BHR and those 
who did not; †Analysis of difference in scores among the 5 BHR groups.
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Fig. 1. Graph of the changes in FEV1 according to BHR grade by increasing dose-step. The linear mixed effect analysis showed that the methacholine dose-step af-
fected ΔFEV1%. The BHR grades also affected ΔFEV1%. FEV1, forced expiratory volume in 1 second; BHR, bronchial hyperresponsiveness; ΔFEV1%, percentage fall 
in the forced expiratory volume in 1 second from baseline.
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One interesting finding was that the dose-step was indepen-
dently associated with dyspnea perception. This study was the 
first to evaluate the complex relationships among dyspnea per-
ception, lung function decrease, degree of BHR, and metha-
choline dose-step during the provocation test in children with 
clinical asthma.
Asthmatic children specifically present with dyspnea, wheezy 
breathing, and lung function decline when exposed to bronchi-
al stimulants. The latter 2 items have been widely used to assess 
BHR;6,16 however, dyspnea is seldom utilized as a means to as-
sess BHR. This may be because dyspnea perception is multi-di-
mensional and difficult to score by a single scale, too obscure to 
verify via replication, or too subjective to allow for precise com-
parisons between subjects.17 A previous study evaluated the de-
gree of dyspnea in asthmatic children and reported that dys-
pnea assessed by the visual analog scale (VAS) in real life differs 
according to airway obstruction defined by FEV1 values <80% 
of the predicted values.18 Another study suggested a VAS score 
of ≥6 as a reliable cutoff for subjects who perceive asthma 
symptoms in adult asthmatics.19 These studies consistently 
show that subjects with poorer lung function exhibit a higher 
degree of dyspnea, which was in accordance with the findings 
in the present study. However, these studies did not give any in-
formation on the subjects’ inherent BHR, which we assessed 
during the bronchial provocation test.
Regarding dyspnea measured during induced bronchocon-
striction, most studies have focused only on the dyspnea per-
ception score at a 20% decrease in FEV1 relative to baseline 
(PS20).20-22 As an index of the awareness of asthma symptoms, 
PS20 is useful in differentiating between hypo-, normo-, or hy-
per-perceivers. Identifying children’s perceiving patterns can 
help precisely interpret the level of control and prescribe ap-
propriate controller medications.21 However, PS20 does not cov-
er subjects with BHR-negative clinical asthma whose PS20 can-
not be calculated and it does not contain information on each 
subject’s degree of BHR. One study calculated the Borg slope by 
plotting each subject’s Borg scores against their fall in FEV1.22 
The Borg slope presented good associations with the baseline 
lung function and the cumulative dose of bronchial stimulant 
causing a 20% fall in FEV1. These studies consistently found 
that BHR correlates with symptom perception, in other words, 
children with more severe BHR would perceive their dyspnea 
as less severe.
In the present study, we focused on the multi-dimensional as-
pect of dyspnea. When we confined the analysis to subjects 
with BHR-negative clinical asthma, the median dyspnea score 
ranged from 0.5 to 3, although these subjects had no significant 
lung function decline. Moreover, they presented a trend of in-
creasing dyspnea in accordance with increasing dose-steps. Be-
cause an increase in dose-step involves exposure to more stim-
ulant for a longer time, the increasing dose-steps themselves 
may have affected the subjects psychologically, or the bronchi-
al stimulant inhaled during the challenge tests may have 
caused unpleasant feelings in the asthmatic children. There-
fore, we speculated that the increase in dose along with the lon-
ger duration of exposure may have confounded their dyspnea 
perception and even reversed the dyspnea perception related 
to BHR. Indeed, when we divided the subjects according to 
their BHR grades, we found a trend of more severe dyspnea 
perception corresponding to more severe BHR, which is the 
opposite of previous findings. This discrepancy points toward 
the complexity of dyspnea perception, which is the sum of vari-
ous factors, such as lung function decline, amount of inhaled 
stimulant, and subjects’ degree of BHR at the time of bronchial 
constriction.
Among various indices of dyspnea, we selected the mBorg 
scale because it was widely used in assessing PS20 in previous 
studies.21-24 However, the Borg scale was not invented specifi-
cally for asthmatic subjects, but rather intended for assessing 
fatigue by any cause. Furthermore, pediatric patients might not 
fully understand the difference in degrees of dyspnea when it is 
expressed in words rather than through the VAS.25-27 Moreover, 
it is still unclear whether children are impaired in this complex 
process of cognition, interpretation, and scoring, and, if yes, 
how much they are impaired.
The present study is a re-analysis of data from another study 
that aimed to validate a dyspnea scale complemented by picto-
grams.10 Unfortunately, we did not collect information on clini-
cal severity or the duration of asthma symptoms when enroll-
ing subjects in the initial study. This would have allowed us to 
estimate the proportion of chronic severe asthmatics, which 
may have influenced the association between the bronchocon-
striction and dyspnea perception. Moreover, the season of 
bronchial challenges or the time elapsed since the subjects’ last 
exacerbation may have influenced their asthma control status 
and affected the relationship between dyspnea and the other 
pulmonary function parameters.28,29 Children with severe per-
sistent asthma typically have blunted dyspnea perception due 
to their declined lung function.8,22,30
In this study, we investigated dyspnea intentionally induced 
by a nonspecific and direct stimulus. In reality, dyspnea per-
ceived during asthma exacerbation might originate from differ-
ent sources. Therefore, the generalizability of our findings to 
asthmatic children experiencing natural exacerbation is limit-
ed. However, our findings do suggest that PS20 values are insuf-
ficient for categorizing asthmatic subjects; clinicians should 
take into account the degree of BHR. Further studies on this 
topic should adopt an exercise challenge test rather than a 
methacholine test, because such graded challenges cannot be 
free from the psychological issues that accompany repeated 
procedures. More clinical information, including the asthma 
duration, clinical severity, and other demographic variables, 
would also be helpful to adjust for confounding factors.
In conclusion, the evaluation of dyspnea perceived during in-
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duced bronchoconstriction is complex. In asthmatic children, 
inhaled methacholine, as well as the degree of BHR and lung 
function decline, may affect dyspnea perception during the 
bronchial provocation test. Contrary to previous findings, more 
severe BHR presents as more severe dyspnea when the effect of 
the methacholine inhaled during the increased dose-steps is 
considered. If we wish to draw meaningful information from an 
assessment of dyspnea perception, we have to consider various 
complicating factors underlying it.
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